JP2022110143A5 - - Google Patents

Download PDF

Info

Publication number
JP2022110143A5
JP2022110143A5 JP2022083947A JP2022083947A JP2022110143A5 JP 2022110143 A5 JP2022110143 A5 JP 2022110143A5 JP 2022083947 A JP2022083947 A JP 2022083947A JP 2022083947 A JP2022083947 A JP 2022083947A JP 2022110143 A5 JP2022110143 A5 JP 2022110143A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
therapeutic agent
dimethylpyridin
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022083947A
Other languages
English (en)
Japanese (ja)
Other versions
JP7288999B2 (ja
JP2022110143A (ja
Filing date
Publication date
Priority claimed from JP2019521248A external-priority patent/JP7079777B2/ja
Application filed filed Critical
Publication of JP2022110143A publication Critical patent/JP2022110143A/ja
Publication of JP2022110143A5 publication Critical patent/JP2022110143A5/ja
Application granted granted Critical
Publication of JP7288999B2 publication Critical patent/JP7288999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022083947A 2017-06-01 2022-05-23 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤 Active JP7288999B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513692P 2017-06-01 2017-06-01
US62/513,692 2017-06-01
JP2019521248A JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤
PCT/JP2018/020638 WO2018221545A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019521248A Division JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Publications (3)

Publication Number Publication Date
JP2022110143A JP2022110143A (ja) 2022-07-28
JP2022110143A5 true JP2022110143A5 (cg-RX-API-DMAC7.html) 2023-05-18
JP7288999B2 JP7288999B2 (ja) 2023-06-08

Family

ID=64455958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521248A Active JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤
JP2022083947A Active JP7288999B2 (ja) 2017-06-01 2022-05-23 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019521248A Active JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Country Status (13)

Country Link
US (1) US11833146B2 (cg-RX-API-DMAC7.html)
EP (1) EP3632439B1 (cg-RX-API-DMAC7.html)
JP (2) JP7079777B2 (cg-RX-API-DMAC7.html)
KR (1) KR102627787B1 (cg-RX-API-DMAC7.html)
CN (1) CN110603040B (cg-RX-API-DMAC7.html)
AU (1) AU2018276565A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019023569A2 (cg-RX-API-DMAC7.html)
CA (1) CA3060030A1 (cg-RX-API-DMAC7.html)
ES (1) ES2980131T3 (cg-RX-API-DMAC7.html)
IL (1) IL270395B (cg-RX-API-DMAC7.html)
RU (1) RU2019135834A (cg-RX-API-DMAC7.html)
SG (2) SG11201909595VA (cg-RX-API-DMAC7.html)
WO (1) WO2018221545A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) * 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DE69518075T2 (de) 1994-05-24 2001-03-22 F. Hoffmann-La Roche Ag, Basel Tricyclische dicarbonylderivate
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2007332439A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
AU2010219598A1 (en) 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JP2013051639A (ja) 2011-08-31 2013-03-14 Kyocera Document Solutions Inc 画像形成装置
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
SI2573073T1 (sl) 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
CN103930423B (zh) 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
JP5666755B1 (ja) 2013-04-05 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
CN108563565B (zh) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 飞行着陆引导系统可靠性定量分析模型建立方法

Similar Documents

Publication Publication Date Title
IL270395B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
JP2019059760A5 (cg-RX-API-DMAC7.html)
ES2236185T3 (es) Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o neuropatico y migrañas.
ES2358763T3 (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2020521726A5 (cg-RX-API-DMAC7.html)
ES2318771T3 (es) 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
JP2005515964A5 (cg-RX-API-DMAC7.html)
FI3856182T3 (fi) Koostumuksia ja menetelmiä muskariinireseptorin aktivaation lievittämien häiriöiden hoitamiseksi
IL270394B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
JPH09511739A (ja) フィブロミアルギアの処置のためのセロトニンアンタゴニスト(5ht▲下3▼)の使用
CN104768540A (zh) 抗胆碱能神经保护组合物和方法
WO2007108010B1 (en) Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
JP2004506682A5 (cg-RX-API-DMAC7.html)
JP2005522432A5 (cg-RX-API-DMAC7.html)
JP2002535370A5 (cg-RX-API-DMAC7.html)
JP2015522592A5 (cg-RX-API-DMAC7.html)
SK22004A3 (sk) Farmaceutická kompozícia na moduláciu cholínergnej funkcie a použitie kombinácie NRPA zlúčeniny a antiemetického/antinauzeózneho činidla na výrobu liečiva
KR102393649B1 (ko) 알츠하이머병 또는 인지기능장애 치료를 위한 도네페질 및 타다라필 병용 요법
US20170326107A1 (en) 5-HT6 Receptor Antagonists for Use in the Treatment of Alzheimer's Disease with Apathy as Comorbiity
CN115702143A (zh) 治疗系统性硬化症的方法
JP2006513207A (ja) 行動障害の治療のためのイストラデフィリン(kw−6002)の使用
US20050250806A1 (en) Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
CA2416706C (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
JP3411292B2 (ja) ジスキネジー用5−ht3レセプターアンタゴニスト